SI3634377T1 - Farmacevtska formulacija - Google Patents

Farmacevtska formulacija

Info

Publication number
SI3634377T1
SI3634377T1 SI201830368T SI201830368T SI3634377T1 SI 3634377 T1 SI3634377 T1 SI 3634377T1 SI 201830368 T SI201830368 T SI 201830368T SI 201830368 T SI201830368 T SI 201830368T SI 3634377 T1 SI3634377 T1 SI 3634377T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
SI201830368T
Other languages
English (en)
Inventor
Scott Boyer
Fredrik Hubinette
Leif Ingemarsson
Susan Suchdev
Original Assignee
Klaria Pharma Holding Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klaria Pharma Holding Ab filed Critical Klaria Pharma Holding Ab
Publication of SI3634377T1 publication Critical patent/SI3634377T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI201830368T 2017-06-08 2018-06-08 Farmacevtska formulacija SI3634377T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1709141.4A GB201709141D0 (en) 2017-06-08 2017-06-08 Pharmaceutical formulation
PCT/EP2018/065223 WO2018224674A1 (en) 2017-06-08 2018-06-08 Pharmaceutical formulation
EP18729683.5A EP3634377B1 (en) 2017-06-08 2018-06-08 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
SI3634377T1 true SI3634377T1 (sl) 2021-11-30

Family

ID=59358417

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201830368T SI3634377T1 (sl) 2017-06-08 2018-06-08 Farmacevtska formulacija

Country Status (19)

Country Link
US (3) US11219600B2 (sl)
EP (2) EP3932399A1 (sl)
CN (1) CN110831575A (sl)
AU (1) AU2018279192A1 (sl)
BR (1) BR112019025552A2 (sl)
CA (1) CA3056992A1 (sl)
DK (1) DK3634377T3 (sl)
ES (1) ES2881710T3 (sl)
GB (1) GB201709141D0 (sl)
HR (1) HRP20211323T1 (sl)
HU (1) HUE055884T2 (sl)
IL (1) IL271226A (sl)
MX (1) MX2019012435A (sl)
PL (1) PL3634377T3 (sl)
PT (1) PT3634377T (sl)
RU (1) RU2019139286A (sl)
SI (1) SI3634377T1 (sl)
WO (1) WO2018224674A1 (sl)
ZA (1) ZA201906318B (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3541362A1 (en) 2016-11-15 2019-09-25 Klaria Pharma Holding AB Pharmaceutical formulation
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
GB201911715D0 (en) * 2019-08-15 2019-10-02 Klaria Pharma Holding Ab Film formulation comprising carriers
GB201912505D0 (en) * 2019-08-30 2019-10-16 Klaria Pharma Holding Ab Pharmaceutical formulation
EP4100012A4 (en) * 2020-02-05 2024-02-07 Summit Biosciences Inc MEDICINAL PRODUCTS INTENDED TO BE ADMINISTERED BY INTRANASAL ROUTE AND ASSOCIATED USES
DE102021105268A1 (de) 2021-03-04 2022-09-08 Lts Lohmann Therapie-Systeme Ag. Oraler Dünnfilm
US20240009184A1 (en) * 2022-03-11 2024-01-11 John Abernethy Opioid overdose reversal mixtures

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933462A (en) 1958-12-17 1963-08-08 Simone Marie Antoinette Radouc Improvements in or relating to the treatment of meat
US5288498A (en) 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5785989A (en) 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
WO1998001134A1 (en) 1996-07-10 1998-01-15 Novartis Consumer Health S.A. Oral pharmaceutical combinations of antihistaminic compounds and terpenoids
AU3444297A (en) 1996-07-12 1998-02-09 Novartis Consumer Health S.A. Oral pharmaceutical combinations of nsaids with terpenoids
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
KR100452972B1 (ko) 2000-05-16 2004-10-14 주식회사 삼양사 경피투여용 하이드로젤 조성물
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20040247649A1 (en) 2002-02-11 2004-12-09 Edizone, Lc Medicine-containing orally soluble films
WO2008095144A2 (en) 2007-01-31 2008-08-07 Rutgers, The State University Of New Jersey Controlled release of actives in skin
US20060257463A1 (en) 2002-05-31 2006-11-16 University Of Mississippi Transmucosal delivery of cannabinoids
DE10226494A1 (de) 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
GB0217382D0 (en) 2002-07-26 2002-09-04 Pfizer Ltd Process for making orally consumable dosage forms
US9561182B2 (en) 2003-08-22 2017-02-07 Cure Pharmaceutical Corporation Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals
US20040096569A1 (en) 2002-11-15 2004-05-20 Barkalow David G. Edible film products and methods of making same
US9498454B2 (en) 2003-02-24 2016-11-22 Pharmaceutical Productions Inc. Transmucosal drug delivery system
ES2414084T3 (es) 2003-02-24 2013-07-18 Pharmaceutical Productions Inc. Sistema de administración de fármacos por vía transmucosa
WO2005004989A2 (en) 2003-07-01 2005-01-20 Todd Maibach Film comprising therapeutic agents
KR20050048056A (ko) 2003-11-18 2005-05-24 (주)케이비피 경구용 소모 필름 조성물
CA2578201A1 (en) 2004-08-23 2006-03-02 Mark Rosenberg Formulations and methods for modulating satiety
LT2486942T (lt) 2004-11-24 2019-01-25 Meda Pharmaceuticals Inc. Kompozicijos, apimančios azelastiną ir jų panaudojimo būdai
US20060217308A1 (en) 2005-03-10 2006-09-28 Pascale Cossart Compositions for the treatment of tumor pathologies, comprising internalin B (ln1B) of Listeria monocytogene protein or a fragment thereof
AU2006202528B2 (en) 2005-03-15 2008-01-03 Animal Ethics Pty Ltd A topical analgesic composition
US20070059361A1 (en) 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
GB2423711B (en) 2005-10-24 2007-02-14 Fortune Apex Dev Ltd Method for preparing a pharmaceutical composition with enhanced mucoadhesion
SE530184C2 (sv) * 2005-12-23 2008-03-18 Kjell Stenberg Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater
IL175338A0 (en) 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
CN101081218A (zh) 2006-06-02 2007-12-05 范敏华 一种口腔速崩膜及其制备方法
US20070293581A1 (en) 2006-06-05 2007-12-20 Malcolm Hill Methods for Buccal, Lingual or Sublingual Dosing Regimens of Epinephrine for the Treatment of Allergic Emergencies
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
KR100855566B1 (ko) 2006-09-12 2008-09-03 (주) 아모젠 경구용 소모성 필름
EP2404934A1 (en) 2006-09-22 2012-01-11 Novo Nordisk A/S Protease resistant insulin analogues
US20080269347A1 (en) 2006-09-28 2008-10-30 Azopharma, Inc. Epinephrine formulations
JP2010512413A (ja) 2006-12-11 2010-04-22 ケムファーム・インコーポレーテッド アンフェタミンの非標準アミノ酸結合体およびそれらの製造方法および使用方法
WO2008098195A2 (en) 2007-02-09 2008-08-14 Todd Maibach Film comprising nitroglycerin
US20090246273A1 (en) 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Ketorolac Sublingual Spray for the Treatment of Pain
WO2009126132A1 (en) 2008-03-31 2009-10-15 Mark Rosenberg Formulations and methods for modulating satiety
RU2519193C2 (ru) 2008-09-12 2014-06-10 Критикал Фармасьютикалс Лимитед Усовершенствование всасывания терапевтических средств через слизистые оболочки или кожу
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
US8900634B2 (en) 2008-11-03 2014-12-02 Nal Pharmaceuticals, Ltd. Diethylstilbestrol dosage form and methods of treatment using thereof
CN101574330A (zh) 2009-06-12 2009-11-11 上海现代药物制剂工程研究中心有限公司 苯甲酸利扎曲普坦膜剂
KR101074271B1 (ko) 2009-06-25 2011-10-17 (주)차바이오앤디오스텍 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름
US8475832B2 (en) * 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
EP2480197B1 (en) 2009-09-25 2015-11-11 Dr. Reddy's Laboratories Ltd. Formulations comprising triptan compounds
PL2493457T3 (pl) 2009-10-30 2018-01-31 Ix Biopharma Ltd Szybko rozpuszczalna stała postać dawkowana
KR101077468B1 (ko) 2011-03-04 2011-11-07 (주)차바이오앤디오스텍 안정한 경구용 속용 필름 제제
KR101303479B1 (ko) 2011-07-28 2013-09-06 (주)씨엘팜 가식성 필름형성 조성물 및 약물이 함유된 가식성 필름형 제제
US20140171510A1 (en) 2011-07-29 2014-06-19 Shire Llc Homoarginine prodrugs and/or conjugates of amphetamine and other stimulants and processes for making and using the same
CA2850964C (en) 2011-10-05 2021-02-02 Jennifer L. Sanders Methods and compositions for treating foot or hand pain
CA2853084C (en) 2011-10-21 2022-04-26 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
WO2013171146A1 (en) * 2012-05-15 2013-11-21 Lts Lohmann Therapie-Systeme Ag Oral film containing enteric release opiate resinate
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
FR2994844B1 (fr) 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
CN102871984B (zh) 2012-11-05 2015-11-11 天津市聚星康华医药科技有限公司 一种盐酸去氧肾上腺素口腔速溶膜及其制备方法
CN102961365B (zh) 2012-12-17 2016-01-20 天津市聚星康华医药科技有限公司 硫酸特布他林口腔速溶膜及其制备方法
WO2014137189A1 (ko) 2013-03-07 2014-09-12 에스케이케미칼주식회사 고함량의 약물을 함유하는 구강 붕해 필름 및 이의 제조방법
WO2014160404A1 (en) 2013-03-13 2014-10-02 The Regents Of The University Of California Improved oral drug devices and drug formulations
WO2014202088A1 (en) 2013-06-17 2014-12-24 Rigshospitalet Injectable pharmaceutical compositions comprising adrenaline and citric acid
DE202013105715U1 (de) 2013-08-22 2014-02-19 Sipnose Ltd. Vorrichtung zur Abgabe einer vorbestimmten Menge einer Substanz an eine natürliche Öffnung des Körpers
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
EP3071189A1 (en) 2013-11-19 2016-09-28 Rigshospitalet Injectable pharmaceutical compositions comprising iloprost
EP3082816B1 (en) 2013-12-20 2019-03-20 Indivior UK Limited Intranasal naloxone compositions and methods of making and using same
AU2015247649B2 (en) 2014-04-15 2019-01-17 Propella Therapeutics, Inc. Topical compositions for pain relief, manufacture and use
US9044390B1 (en) 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
CA2952622A1 (en) 2014-06-16 2015-12-23 Loewi LLC Methods of anesthetizing nerve tissue in the trigeminal nerve pathway and medical uses thereof
US10307397B2 (en) 2014-07-28 2019-06-04 Concept Matrix Solutions Oral dissolvable film that includes plant extract
RS58120B1 (sr) * 2014-07-31 2019-02-28 Pharmathen Sa Kompozicija orodisperzibilnog filma koja sadrži enalapril za lečenje hipertenzije kod pedijatrijske populacije
US10383950B2 (en) 2014-08-14 2019-08-20 Helmholtz-Zentrum Fur Infektionsforschung Gmbh (De/De) Methods and compositions of carrier systems for the purpose of intracellular drug targeting
CN105878171A (zh) * 2014-12-22 2016-08-24 南京海恒医药科技有限公司 一种依达拉奉新制剂及其制备方法
US10335398B2 (en) 2015-04-08 2019-07-02 Maxinase Life Sciences Limited Bioadhesive compositions for intranasal administration of granisetron
US10064816B2 (en) 2015-06-11 2018-09-04 ReJoy Treatment of sexual dysfunction
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US10898537B2 (en) 2015-07-31 2021-01-26 Delivra Inc. Transdermal formulations for delivery of capsaicinoids
US20170079907A1 (en) 2015-09-18 2017-03-23 Insys Development Company, Inc. Sublingual Epinephrine Spray
US10039710B2 (en) 2015-09-18 2018-08-07 Insys Development Company, Inc. Epinephrine spray formulations
US9833461B2 (en) 2015-10-23 2017-12-05 Ctt Pharma Inc. Therapeutic compositions comprising cannabidiol and corticosteroids
ES2949053T3 (es) 2016-01-07 2023-09-25 Viramal Ltd Composiciones de gel para administración transdérmica para maximizar las concentraciones de fármaco en el estrato córneo y suero, y métodos de uso de las mismas
EP3407976A4 (en) 2016-01-26 2019-07-17 Levation Pharma Ltd. COMPOSITIONS AND USES OF ALPHA-ADRENERGIC AGENTS
WO2017135195A1 (ja) 2016-02-03 2017-08-10 社会医療法人蘇西厚生会 まつなみリサーチパーク アレルギー症状の予防又は治療剤
CA3020798A1 (en) 2016-04-12 2017-10-19 Scott SCHANEVILLE Ingestible films having substances from hemp or cannabis
US20180104195A1 (en) 2016-05-05 2018-04-19 Monosol Rx, Llc Enhanced delivery epinephrine compositions
BR112018072467A2 (pt) 2016-05-05 2019-02-19 Aquestive Therapeutics, Inc. composições farmacêuticas com permeação aumentada
US20180125977A1 (en) 2016-05-05 2018-05-10 Monosol Rx, Llc Enhanced delivery epinephrine compositions
KR20190005199A (ko) 2016-05-05 2019-01-15 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물
WO2017218918A1 (en) 2016-06-17 2017-12-21 Ys Pharmtech Stabilization of epinephrine formulations
EP3541362A1 (en) 2016-11-15 2019-09-25 Klaria Pharma Holding AB Pharmaceutical formulation
CN107080745A (zh) 2017-04-14 2017-08-22 宁夏医科大学 一种载叶黄素白蛋白纳米粒的口腔速溶膜及其制备方法
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
GB201807942D0 (en) 2018-05-16 2018-06-27 Klaria Pharma Holding Ab Pharmaceutical formulation
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
GB201911715D0 (en) 2019-08-15 2019-10-02 Klaria Pharma Holding Ab Film formulation comprising carriers
GB201912505D0 (en) 2019-08-30 2019-10-16 Klaria Pharma Holding Ab Pharmaceutical formulation
EP4054523A1 (en) 2019-11-04 2022-09-14 Maabarot Products Ltd. Orally administrable films comprising poorly water soluble active ingredients and preparation thereof

Also Published As

Publication number Publication date
HRP20211323T1 (hr) 2021-11-26
BR112019025552A2 (pt) 2020-06-23
PT3634377T (pt) 2021-10-18
GB201709141D0 (en) 2017-07-26
ZA201906318B (en) 2022-05-25
RU2019139286A3 (sl) 2022-03-03
US20240165022A1 (en) 2024-05-23
WO2018224674A1 (en) 2018-12-13
EP3932399A1 (en) 2022-01-05
US11904049B2 (en) 2024-02-20
US11219600B2 (en) 2022-01-11
EP3634377A1 (en) 2020-04-15
MX2019012435A (es) 2020-01-13
RU2019139286A (ru) 2021-07-09
US20200246253A1 (en) 2020-08-06
AU2018279192A1 (en) 2019-10-17
WO2018224674A9 (en) 2019-03-21
IL271226A (en) 2020-01-30
EP3634377B1 (en) 2021-07-21
CN110831575A (zh) 2020-02-21
ES2881710T3 (es) 2021-11-30
DK3634377T3 (da) 2021-08-30
CA3056992A1 (en) 2018-12-13
HUE055884T2 (hu) 2021-12-28
PL3634377T3 (pl) 2021-12-20
US20220160618A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
GB201807942D0 (en) Pharmaceutical formulation
IL269061A (en) A pharmaceutical preparation containing Selexifag
ZA201903101B (en) Pharmaceutical formulations
IL271226A (en) medical preparation
IL271759B1 (en) Pharmaceutical preparations that include anthraxtinib
PT3426294T (pt) Formulação farmacêutica compreendendo anticorpo, ciclodextrina e metionina
ZA202102871B (en) Pharmaceutical formulation
IL253177B (en) Pharmacy preparation
IL269239A (en) A pharmaceutical combination containing fonsimod
IL278927A (en) pharmaceutical preparation
HK1245653A1 (zh) 藥物製劑
IL266537A (en) pharmaceutical preparation
ZA201807851B (en) Pharmaceutical formulation
FI3601277T3 (fi) Farmaseuttinen formulaatio
EP3383371A4 (en) PHARMACEUTICAL FORMULATION
GB201506755D0 (en) Novel pharmaceutical formulation
EP3727485C0 (en) PHARMACEUTICAL COMPOSITION
IL275144A (en) Pharmacy preparation
GB201511246D0 (en) Pharmaceutical formulation
IL271908A (en) Over-compressed pharmaceutical preparations
GB201719873D0 (en) Pharmaceutical formulation
GB201604545D0 (en) Novel pharmaceutical formulation
GB201610440D0 (en) Pharmaceutical formulations